Amber Bowling
Family · Baton Rouge, LANPI 1487079257
Payments from drug & device makers
Across 117 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$538
- Lilly USA, LLC$240
- GSK$178
- Corium, LLC$173
- Novo Nordisk$106
- Pfizer$94
- plus $582 from 15 others
What the payments were for
- Food & beverage$1,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $538 |
| Lilly USA, LLC | 15 | $240 |
| GSK | 8 | $178 |
| Corium, LLC | 11 | $173 |
| Novo Nordisk | 6 | $106 |
| Pfizer | 5 | $94 |
| Tris Pharma Inc | 5 | $89 |
| Exact Sciences | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| AstraZeneca | 3 | $46 |
| Antares Pharma, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Amgen | 2 | $35 |
| Halozyme Inc | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
How this compares
$1,911 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 18 | $18,212 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,604 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $1,374 |
| Bupropion XlBupropion Hcl | 29 | $721 |
| Gabapentin | 48 | $714 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $420 |
| Atorvastatin Calcium | 25 | $320 |
| Ondansetron OdtOndansetron | 11 | $316 |
| Rosuvastatin Calcium | 19 | $312 |
| Fluticasone Propionate | 18 | $309 |
| Famotidine | 21 | $287 |
| Meloxicam | 32 | $273 |
| Zolpidem Tartrate | 14 | $262 |
| Amlodipine Besylate | 44 | $261 |
| Pantoprazole Sodium | 26 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $240 | $18,21218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Baton Rouge
- Elidia DewittBaton Rouge$108K
- Ghenet GhebretatiosBaton Rouge$91K
- Heather SullivanBaton Rouge$32K
- Randee KidderBaton Rouge$30K
- Dionne BellBaton Rouge$25K
- Jennifer LittleBaton Rouge$21K
- Tracy ParkerBaton Rouge$19K
- Celeste WaguespackBaton Rouge$18K
- Kristen VillarBaton Rouge$18K
- Sharon JacksonBaton Rouge$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.